LONDON, 18 September, 2017:

Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “Arix”), a global healthcare and life science company supporting medical innovation, is today hosting its inaugural Capital Markets Meeting for investors and analysts in London.

Joe Anderson, Chief Executive Officer, and Jonathan Peacock, Chairman, will provide an update on Arix Bioscience’s strategy and progress to date. The event will also include presentations from additional members of the Arix Bioscience team as well as a number of Arix Group Businesses, who will each provide a detailed overview of their respective companies, objectives and potential.

The meeting will be held at Etc. Venues 8 Fenchurch Place, Fenchurch Street, London EC3M 4PB, from 12:30 to 18:00 BST. The event will start with an informal lunch buffet, followed by a series of short presentations, question-and-answer sessions and networking. No new material information will be disclosed.

Presenters at the Arix Capital Markets Meeting will include:

  • Joe Anderson, PhD, CEO of Arix Bioscience plc
  • Jonathan Peacock, Chairman of Arix Bioscience plc
  • Daniel O’Connell, MD, PhD, Arix Bioscience plc
  • Mark Chin, Arix Bioscience plc
  • Christian Itin, PhD, CEO and Chairman of Autolus
  • Niall Martin, PhD, CEO of Artios Pharma
  • Jerry McMahon, PhD, President and CEO of Harpoon Therapeutics
  • Corey Fishman, MSM, CEO of Iterum Therapeutics
  • Gordon Hamilton, MA MD MBBS MBA, CEO of Depixus
  • Mike Moran, MBE, CEO of Proton Partners International

A live webcast of the event, with presentation slides, will be available on the Arix website at: A replay will be available on the website shortly after the event.